Director at ClearPoint Neuro (NASDAQ: CLPT) gains 12,417 shares via RSU vesting

Rhea-AI Filing Summary

FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.

ClearPoint Neuro director R. John Fletcher increased his direct holdings through routine equity compensation. On May 19, 2026, 12,417 restricted stock units vested and were settled into 12,417 shares of common stock, with no open-market buying or selling involved.

These RSUs were originally granted on May 22, 2025 and vested on their scheduled date, tied to the first anniversary or the day before the 2026 annual stockholder meeting. Following the settlement, Fletcher directly holds 130,349 shares of ClearPoint Neuro common stock.

Insider Trade Summary

12,417 shares exercised/converted

Mixed 2 txns

Insider FLETCHER R JOHN

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	12,417	$0.00	--
Exercise	Common Stock	12,417	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 130,349 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs settled: 12,417 units Shares acquired from RSUs: 12,417 shares Post-transaction holdings: 130,349 shares

3 metrics

RSUs settled 12,417 units Restricted stock units vested and converted on May 19, 2026

Shares acquired from RSUs 12,417 shares Common stock received upon RSU settlement

Post-transaction holdings 130,349 shares Director’s direct ClearPoint Neuro common stock after transaction

Key Terms

Restricted Stock Units, derivative security, scheduled vesting date

3 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

scheduled vesting date financial

"This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FLETCHER R JOHN

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		M		12,417	A	(1)	130,349	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/19/2026		M			12,417	(1)	(1)	Common Stock	12,417	(1)	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

	/s/ Danilo D'Alessandro, by Power of Attorney for R. John Fletcher	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider activity did ClearPoint Neuro (CLPT) report for R. John Fletcher?

ClearPoint Neuro reported that director R. John Fletcher received 12,417 shares of common stock from vesting restricted stock units. This Form 4 shows routine equity compensation settlement, not an open-market purchase or sale of CLPT shares.

How many ClearPoint Neuro (CLPT) shares did R. John Fletcher acquire in this Form 4?

R. John Fletcher acquired 12,417 ClearPoint Neuro common shares when his restricted stock units vested. Each unit converted into one share, reflecting scheduled settlement of a prior equity grant rather than a new market transaction in CLPT stock.

What are the details of the restricted stock units reported for ClearPoint Neuro (CLPT)?

The filing states Fletcher was granted 12,417 restricted stock units on May 22, 2025. These units vested on the earlier of the first anniversary of that grant date or the day before ClearPoint Neuro’s 2026 annual stockholder meeting, then settled into common shares.

Does the ClearPoint Neuro (CLPT) Form 4 show any open-market buying or selling?

The Form 4 does not show open-market buying or selling. It reports the vesting and settlement of 12,417 restricted stock units into common shares, a compensation-related equity conversion rather than a discretionary trade in CLPT stock.

How many ClearPoint Neuro (CLPT) shares does R. John Fletcher hold after this transaction?

After the RSU settlement, R. John Fletcher directly holds 130,349 shares of ClearPoint Neuro common stock. This total reflects his post-transaction ownership as reported in the Form 4, including the 12,417 newly issued shares from vested restricted stock units.

What was the grant date for the ClearPoint Neuro (CLPT) restricted stock units?

The filing notes that Fletcher’s 12,417 restricted stock units were granted on May 22, 2025. They were structured to vest on the earlier of the first anniversary of that date or the day immediately preceding ClearPoint Neuro’s 2026 annual meeting of stockholders.